Qiagen : Strong Q2 triggers slight increase in FY 2024 guidance – still limited upside to unchanged TP
>Strong Q2 figures above expectations and guidance - Qiagen reported a good set of Q2 results. Sales at CER came in at $ 502m, 1% above our ($ 497m) and consensus estimates ($ 495m) as well as ahead of the company’s guidance of $ 495m. Y-o-y, sales increased by 1% despite Qiagen’s solution to gradually exit the NeuMoDx business. Adjusted for NeuMoDx CER sales increased by 2%. Adjusted operating income of $ 141m (+4%) was 2% above our estimates of $138m and 3% ahead...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.